KDV B — Kdventures AB Share News
0.000.00%
Last trade - 00:00- SEK185.53m
- SEK138.12m
- SEK1.67m
Brief: KDventures' Modus Therapeutics Pauses Enrollment In Phase 2A Study
Brief: KDventures' AnaCardio Raises €62.5 Million
Brief: Kdventures' Umecrine Cognition Gets Two USPTO Notices Of Allowance For Patent Applications
Brief: Kdventures' Modus Therapeutics Carries Out Directed Issue
Life sciences investor KDventures Q2 net loss widens on portfolio revaluations
Brief: Kdventures Q2 Net Income SEK -451 Million
Brief: KD Ventures' Pharmnovo Secures Capital Ahead Of Phase 2 Study
Brief: KDventures: AnaCardio's AC01 Study Published
Brief: KDventures Carries Out Directed Issue Of Shares
Brief: Umecrine Cognition Completes Sek 19.6 Million Share Issue
Brief: Kdventures Q1 Result Sek -34.1 Million
Brief: Kdventures Portfolio Co Extends IP Protection For AC01 With Patent Approval
Brief: KDventures Says Organon Discontinues Development Of Drug Candidate For PCOS
Brief: KDventures: Reversed Acquisition Of SVF Vaccines By Novakand Pharma Not Completed
Brief: Karolinska Development Q4 Net Loss SEK 39.6 Mln
Brief: Karolinska Development: SVF Vaccines Agrees To Reverse Acquisition With Novakand
Brief: Karolinska Development Says Rights Issue Subscribed To 57%
Brief: Dilafor Signs Term Sheet With Exeltis For License Deal
Brief: Karolinska Development Says Anacardio Reports Positive Phase 2A Trial Results